FDA Adverse Event Injury Summary report: N

MICROPULSE P3 DEVICE

MDR report key: 23774011 · Received December 10, 2025

Report

Report Number
2939653-2024-00029
Event Type
Injury
Date Received
December 10, 2025
Date of Event
March 6, 2024
Report Date
December 10, 2025
Manufacturer
IRIDEX CORPORATION
Product Code
GEX
UDI-DI
00813125015251
PMA / PMN Number
K143154
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
CA, US
Reporter Occupation
003

Narratives

Additional Manufacturer Narrative · 0

CONJUNCTIVAL/SCLERAL BURNS RESOLVE WITHIN 24 TO 48 HOURS. THEREFORE, UNLESS EITHER MEDICAL INTERVENTION OR PERMANENT IMPAIRMENT ARE REPORTED, SCLERAL BURNS ARE NOT DEEMED A SERIOUS ADVERSE EVENT, BECAUSE SCLERAL BURNS TYPICALLY: DO NOT RESULT IN LIFE-THREATENING ILLNESS OR INJURY, DO NOT RESULT IN PERMANENT IMPAIRMENT OF A BODY STRUCTURE OR A BODY FUNCTION, DO NOT REQUIRE HOSPITALIZATION OR PROLONGATION OF PATIENT HOSPITALIZATION, DO NOT REQUIRE MEDICAL OR SURGICAL INTERVENTION TO PREVENT LIFE-THREATENING ILLNESS OR INJURY OR PERMANENT IMPAIRMENT TO A BODY STRUCTURE OR A BODY FUNCTION.

Description of Event or Problem · 0

ON (B)(6) 2024, DURING A TRANSSCLERAL LASER TREATMENT FOR GLAUCOMA USING IRIDEX MICROPULSE P3 PROBE, THE PATIENT SUSTAINED A CONJUNCTIVAL BURN. THE PHYSICIAN IMMEDIATELY STOPPED THE PROCEDURE, REPLACED THE PROBE, AND COMPLETED THE TREATMENT WITHOUT FURTHER COMPLICATIONS. THE PHYSICIAN SUSPECTED THE INITIAL PROBE WAS DEFECTIVE. DEVICE WAS NOT RETURNED TO IRIDEX FOR FURTHER INVESTIGATION. OPHTHALMIC LASER SYSTEMS ARE INTENDED TO DELIVER THERMAL (LASER) ENERGY TO DELIVER AN INSULT (BURN) TO THE CILIARY BODY. CONJUNCTIVAL BURNS ARE A KNOWN AND PREDICTED COMPLICATION ASSOCIATED WITH THE USE OF ANY OPHTHALMIC LASER SYSTEM (CONSOLE AND DELIVERY DEVICE) WHEN USED TO DELIVER TRANSSCLERAL TREATMENT. IT IS LISTED AS A POSSIBLE COMPLICATION IN THE IFU FOR MP3 DELIVERY DEVICE. CONJUNCTIVAL BURNS ARE A SPECIFIC TYPE OF OCULAR BURN THAT CAN OCCUR ALONG WITH CORNEAL BURNS, OFTEN DUE TO CHEMICAL OR THERMAL INJURY AND ARE TYPICALLY SUPERFICIAL, POSING NO LONG-TERM THREAT TO THE PATIENT. TYPICALLY, THESE BURNS RESOLVE WITHIN 24-48 HOURS POST OP WITHOUT ADDITIONAL INTERVENTION. IRIDEX CORPORATION DOES REPORT EVERY ADVERSE EVENT VIA THE FDA'S MANUFACTURER AND USER FACILITY DEVICE EXPERIENCE (MAUDE) DATABASE. POWER SETTINGS USED WAS 2500 MW WITH MICROPULSE SETTING. PATIENT DID NOT HAVE ANY SIGNIFICANT MEDICAL HISTORY. THE PHYSICIAN ADHERED TO THE PROCEDURAL APPROACH AS RECOMMENDED IN THE MP3 PROBE IFU. PROCEDURE WAS ABLE TO BE COMPLETED WITHOUT FURTHER ISSUE. PATIENT WAS SEEN THE FOLLOWING WEEK AND WAS RECOVERING WELL WITH INJURY MOSTLY RESOLVED. ANOTHER FACTOR TO BE TAKEN INTO ACCOUNT IS THAT OCCASIONALLY, THE TIP OF THE PROBE WILL BECOME CONTAMINATED WITH BLOOD OR TISSUE, AND THE CONTAMINANTS ON THE TIP CAN BECOME HATED WHEN EXPOSED TO LASER ENERGY. CONTAMINATION OF THE FIBER OPTIC TIP BY BLOOD OR TISSUE CHAR MAY RESULT IN OCULAR SURFACE BURNS AND A SMOKING TIP OF THE PROBE.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
2009051 MICROPULSE P3 DEVICE MP3 PROBE GEX IRIDEX CORPORATION 00813125015251

Patients

Seq Age Sex Outcome Treatment
1 NA Unknown Other